As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at fair, transparent prices — without interference or price gouging from middlemen.
Several Big Pharma companies have started selling their drugs directly to consumers (DTC). This shift — driven in part by President Trump’s push for lower drug prices and fewer middlemen — has garnered relatively little media coverage.
But the implications for American patients, employers, and the healthcare system as a whole are enormous.
Over the past two decades, the DTC sales model has revolutionized the way Americans buy everything from mattresses to contact lenses.
If DTC sales become the norm in the pharmaceutical industry, patients and employers could save tens of billions of dollars — by cutting out the middlemen who currently profit from the convoluted and opaque drug supply chain at everyone else’s expense.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Drugmakers Are Embracing Direct-To-Consumer Sales. That’s Fantastic News For Patients.
Sally C. Pipes
As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at fair, transparent prices — without interference or price gouging from middlemen.
Several Big Pharma companies have started selling their drugs directly to consumers (DTC). This shift — driven in part by President Trump’s push for lower drug prices and fewer middlemen — has garnered relatively little media coverage.
But the implications for American patients, employers, and the healthcare system as a whole are enormous.
Over the past two decades, the DTC sales model has revolutionized the way Americans buy everything from mattresses to contact lenses.
If DTC sales become the norm in the pharmaceutical industry, patients and employers could save tens of billions of dollars — by cutting out the middlemen who currently profit from the convoluted and opaque drug supply chain at everyone else’s expense.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.